文献速递腹部泌尿生殖MR

钆塞酸二钠增强MRI诊断LI-RADS M类病变:联合血清标志物与影像特征识别含胆管癌的肿瘤

Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
PubMed 文献 · Eur Radiol · 2020-11-27

该研究回顾性纳入45例仅表现为LR-M类病变的高危患者,基于CA19-9、AFP及LI-RADS「肿块内血液产物」特征构建 logistic 回归模型诊断含胆管癌的肿瘤(M-CC)。联合三项指标诊断M-CC的AUC为0.862、敏感度76%、特异度88%;三项标准均满足时M-CC风险为98%,特异度100%。

要点

  • LR-M病变中,CA19-9>38 U/mL、AFP>4.8 ng/mL及缺乏「肿块内血液产物」是M-CC的独立预测因素。
  • 三项指标联合诊断M-CC的AUC为0.862,敏感度76%,特异度88%。
  • 三项标准均满足时M-CC风险达98%,特异度100%。

关键影像表现/征象

  • LI-RADS「肿块内血液产物」特征缺失与M-CC相关。
  • 45例中肝细胞癌19例(42.2%)、肝内胆管癌15例(33.3%)、混合型肝细胞-胆管癌6例(13.3%)、其他肝脏病变5例(11.1%)。

诊断标准与关键数值

  • CA19-9>38 U/mL、AFP>4.8 ng/mL及缺乏LI-RADS「肿块内血液产物」为M-CC的显著预测因素。
  • 三项预测因素联合诊断M-CC的AUC为0.862,敏感度76%,特异度88%。
  • 三项标准均满足时M-CC风险为98%(AUC 0.690,敏感度38%,特异度100%)。

临床应用与阅片要点

  • 对仅表现为LR-M类病变的高危患者,可结合CA19-9>38 U/mL、AFP>4.8 ng/mL及缺乏「肿块内血液产物」综合评估M-CC可能。
  • 三项标准均满足时M-CC风险为98%、特异度100%,原文指出这可能减少或免除活检确认的需要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The LI-RADS M (LR-M) category describes hepatic lesions probably or definitely malignant, but not specific for hepatocellular carcinoma in at-risk patients. Differentiation among LR-M entities, particularly detecting cholangiocarcinoma-containing tumors (M-CCs), is essential for treatment and prognosis. Thus, we aimed to develop diagnostic models on gadoxetate disodium-enhanced MRI comprising serum tumor markers and LI-RADS imaging features for M-CC.

METHODS: Consecutive at-risk patients with LR-M lesions exclusively (no co-existing LR-4 and/or LR-5 lesions) were retrieved retrospectively from a prospectively collected database spanning 3 years. Intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (c-HCC-CCA) were classified together as M-CC. LI-RADS features determined by three independent radiologists and clinically relevant serum tumor markers were used to generate M-CC diagnostic models through logistic regression analysis against histology. Per-patient performance was evaluated using area under the receiver operating curve (AUC), sensitivity, and specificity.

RESULTS: Forty-five patients were included, 42.2% (19/45) with hepatocellular carcinoma, 33.3% (15/45) with ICC, 13.3% (6/45) with c-HCC-CCA, and 11.1% (5/45) with other hepatic lesions. Carbohydrate antigen (CA)19-9 > 38 U/mL, α-fetoprotein (AFP) > 4.8 ng/mL, and absence of the LI-RADS feature "blood products in mass" were significant predictors of M-CC. Combining three predictors demonstrated AUC of 0.862, sensitivity of 76%, and specificity of 88%. The risk of M-CC with all three criteria fulfilled was 98% (AUC, 0.690; sensitivity, 38%; specificity, 100%).

CONCLUSIONS: In at-risk patients with LR-M lesions, integrating CA19-9, AFP, and the LI-RADS feature "blood products in mass" achieved high diagnostic performance for M-CC. When all three criteria were fulfilled, the specificity for M-CC was 100%.

KEY POINTS: • In at-risk patients who had LR-M lesions exclusively (no concomitant LR-4/5 lesions), a model with carbohydrate antigen > 38 U/mL, α-fetoprotein > 4.8 ng/mL, and absence of the LI-RADS feature "blood products in mass" achieved high accuracy for diagnosing cholangiocarcinoma-containing tumors. • In patients of whom all three criteria were fulfilled, the specificity for M-CC was 100%, which might reduce or eliminate the need for biopsy confirmation.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jiang H, Song B, Qin Y, et al. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol. 2020. PMID: 33245494. doi:10.1007/s00330-020-07488-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。